Sugi Predict

Sugi Predict / Compounds / SCHEMBL730895

SCHEMBL730895

SCHEMBL730895

COC(=O)c1ccc(O)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.67
▸ CA1 P00915 6/20 0.67
▸ CA2 P00918 6/20 0.67
▸ CA7 P43166 6/20 0.67
▸ CA9 Q16790 6/20 0.67
▸ CA14 Q9ULX7 6/20 0.67
▸ PDK2 Q15119 1/20 0.67
▸ PDK4 Q16654 1/20 0.67
▸ MAPT P10636 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ CASP3 P42574 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ SENP8 Q96LD8 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54
▸ SENP6 Q9GZR1 1/20 0.54
▸ ABL1 P00519 1/20 0.51
▸ GAA P10253 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.47
▸ EGFR P00533 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1180308 0.85 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL27645324 0.83 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL608814 0.82 ABL1 (0.68) MAPTSMN1; SMN2NPC1CASP3RAB9A
SCHEMBL2884923 0.82 PDK2 (0.57) CA12CA1CA2CA7CA9
SCHEMBL158999 0.82 CA12 (0.74) CA12CA1CA2CA7CA9
SCHEMBL2770364 0.82 PDK2 (0.50) CA12CA1CA2CA7CA9
SCHEMBL335673 0.81 NPC1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL69263 0.81 KDM4E (0.62) CA12CA1CA2CA7CA9
SCHEMBL1496051 0.80 CA12 (0.70) CA12CA1CA2CA7CA9
SCHEMBL2952986 0.80 CA12 (0.71) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113307767-A Synthetic method of lenvatinib 山东汇海医药化工有限公司 2021-08-27 — — CN claimed
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 — — EP disclosed
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-06-05 — — US disclosed
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 — — US disclosed
EP-4452918-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2024-10-30 — — EP disclosed
CN-113754589-B Compositions, methods, and systems for synthesizing and using contrast agents 蓝瑟斯医学影像公司 2024-09-27 — — CN disclosed
WO-2024178390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2024-08-29 — — WO disclosed
EP-3377473-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-06-19 — — EP disclosed
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2024-03-28 — — US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 — — US disclosed
WO-1995002405-A1 BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-01-26 — — WO disclosed
EP-0255236-B1 Fluorine-containing chiral smectic liquid crystals MINNESOTA MINING & MFG (US) 1994-05-04 — — EP disclosed
WO-1994005153-A1 HERBICIDAL BENZENE COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1994-03-17 — — WO disclosed
EP-0360521-B1 Achiral fluorine-containing liquid crystals MINNESOTA MINING & MFG (US) 1993-11-24 — — EP disclosed
US-5254747-A Fluorine-containing chiral smectic liquid crystals MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1993-10-19 — — US disclosed
US-5082587-A ACHIRAL FLUORINE-CONTAINING LIQUID CRYSTALS 3M INNOVATIVE PROPERTIES COMPANY 1992-01-21 — — US disclosed
EP-0360521-A2 Achiral fluorine-containing liquid crystals MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-03-28 — — EP disclosed
US-4886619-A TILTED OR LATENT TILTED MESOPHASES; BLENDS; FERROELECTRIC DEVICE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-12-12 — — US disclosed
EP-0255236-A2 Fluorine-containing chiral smectic liquid crystals MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1988-02-03 — — EP disclosed
US-4179436-A DYEING POLYESTERS BAYER AKTIENGESELLSCHAFT (DE) 1979-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CA12 149/4885CA1 156/4885CA2 1335/4885
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF GRM3, GRM2, GRM1 CA12 2731/4885CA1 1732/4885CA2 990/4885
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CA12 149/4885CA1 156/4885CA2 1335/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 CA12 149/4885CA1 156/4885CA2 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.